IN8bio Terminates LLS Collaboration
Ticker: INAB · Form: 8-K · Filed: Aug 12, 2024 · CIK: 1740279
| Field | Detail |
|---|---|
| Company | In8bio, Inc. (INAB) |
| Form Type | 8-K |
| Filed Date | Aug 12, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: collaboration-termination, intellectual-property, strategic-shift
TL;DR
IN8bio just cut ties with LLS, keeping all the IP. Big strategic move.
AI Summary
On August 12, 2024, IN8bio, Inc. filed an 8-K report to disclose the termination of its agreement with The Leukemia & Lymphoma Society (LLS) regarding the development of novel immunotherapies. The termination was effective immediately, and IN8bio will retain all rights to its intellectual property related to the collaboration.
Why It Matters
This termination signifies a shift in IN8bio's strategic partnerships and potentially impacts the future development trajectory of its immunotherapies previously co-developed with LLS.
Risk Assessment
Risk Level: medium — The termination of a significant collaboration can indicate underlying issues or strategic realignments that may affect future revenue or development timelines.
Key Players & Entities
- IN8bio, Inc. (company) — Registrant
- The Leukemia & Lymphoma Society (LLS) (company) — Collaborating Party
- August 12, 2024 (date) — Filing Date
FAQ
What was the effective date of the termination of the agreement between IN8bio, Inc. and The Leukemia & Lymphoma Society (LLS)?
The termination was effective immediately as of August 12, 2024.
Who is the Registrant in this 8-K filing?
The Registrant is IN8bio, Inc.
What is the primary business of IN8bio, Inc. according to the filing?
IN8bio, Inc. is in the business of Biological Products (No Diagnostic Substances).
What rights does IN8bio, Inc. retain following the termination of the agreement with LLS?
IN8bio, Inc. retains all rights to its intellectual property related to the collaboration.
What is the principal executive office address for IN8bio, Inc.?
The address is 350 5th Avenue, Suite 5330, New York, New York 10118.
Filing Stats: 453 words · 2 min read · ~2 pages · Grade level 10.5 · Accepted 2024-08-12 08:30:00
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share INAB The Nasdaq
Filing Documents
- d801512d8k.htm (8-K) — 25KB
- d801512dex991.htm (EX-99.1) — 24KB
- 0001193125-24-198411.txt ( ) — 179KB
- inab-20240812.xsd (EX-101.SCH) — 3KB
- inab-20240812_lab.xml (EX-101.LAB) — 18KB
- inab-20240812_pre.xml (EX-101.PRE) — 11KB
- d801512d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits . Exhibit No. Description 99.1 Press Release, dated August 12, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. IN8bio, Inc. Dated: August 12, 2024 By: /s/ Patrick McCall Patrick McCall Chief Financial Officer and Secretary (Principal Financial and Accounting Officer)